Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
3.910
-0.100 (-2.49%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Aprea Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 296.42% from the current stock price of 3.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APRE stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +411.51% | Oct 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +181.33% | Aug 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +411.51% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +411.51% | Jun 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +411.51% | Jun 17, 2024 |
Financial Forecast
Revenue This Year
1.14M
from 583.23K
Increased by 96.15%
Revenue Next Year
969.00K
from 1.14M
Decreased by -15.30%
EPS This Year
-2.79
from -3.95
EPS Next Year
-1.04
from -2.79
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.0M | 2.0M | 2.0M | ||
| Avg | 1.1M | 969,000 | 969,000 | ||
| Low | 553,700 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 242.1% | 74.4% | 105.9% | ||
| Avg | 96.1% | -15.3% | - | ||
| Low | -5.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.53 | -1.02 | -0.92 | ||
| Avg | -2.79 | -1.04 | -1.19 | ||
| Low | -3.00 | -1.05 | -1.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.